Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by Wall Street Zen

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

A number of other equities analysts have also commented on the stock. Piper Sandler initiated coverage on shares of Esperion Therapeutics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price target on the stock. Citizens Jmp lifted their price objective on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Friday. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research report on Tuesday, March 10th. Needham & Company LLC increased their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.60.

Esperion Therapeutics Trading Down 1.2%

ESPR stock opened at $2.44 on Friday. The company’s 50 day moving average is $3.28 and its 200 day moving average is $3.15. The stock has a market cap of $626.62 million, a price-to-earnings ratio of -14.35, a price-to-earnings-growth ratio of 1.75 and a beta of 1.11. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to analyst estimates of $165.12 million. As a group, sell-side analysts forecast that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Insider Transactions at Esperion Therapeutics

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 7,337 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total value of $26,926.79. Following the transaction, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at $1,715,816.75. The trade was a 1.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 15,543 shares of company stock worth $55,709. 1.70% of the stock is owned by company insiders.

Institutional Trading of Esperion Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. AIGH Capital Management LLC bought a new stake in Esperion Therapeutics during the 3rd quarter valued at $7,950,000. Two Seas Capital LP grew its holdings in Esperion Therapeutics by 43.6% in the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock worth $9,800,000 after acquiring an additional 3,024,104 shares during the last quarter. Royce & Associates LP bought a new stake in Esperion Therapeutics in the 3rd quarter worth $6,078,000. Integral Health Asset Management LLC purchased a new position in shares of Esperion Therapeutics in the third quarter valued at about $3,975,000. Finally, Diametric Capital LP increased its position in shares of Esperion Therapeutics by 57.8% in the second quarter. Diametric Capital LP now owns 678,824 shares of the biopharmaceutical company’s stock valued at $668,000 after acquiring an additional 248,648 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics News Summary

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Citizens Jmp raised its price target on ESPR to $5.00 (from $4.00) and assigned a “market outperform” rating — implying roughly 105% upside vs. the reference $2.44 level, which could attract buyers and trigger short‑covering. Article Title Article Title
• Neutral Sentiment: Street analysts published Q4 forecasts for ESPR; these refreshes create short‑term volatility but are routine ahead of reporting periods — watch actual Q4 results vs. the new consensus for a catalyst. Article Title
• Negative Sentiment: HC Wainwright lowered multi‑year EPS targets materially while maintaining a “Buy” rating: FY2026 cut to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). The firm also models small quarterly losses (Q1 -$0.08, Q2 -$0.05, Q3 -$0.04) before the projected recovery — the revisions reduce future earnings power embedded in current valuations and likely weigh on the stock. Article Title

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.